Pricing Log in Create free account
Friday 6 November 2026 Export ARWR’s income statement to Excel — free account

Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

58.01 0.55 +0.96%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Arrowhead Pharmaceuticals, Inc. (ARWR) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a EV/Sales of 11.3×. Over the past ten years it has ranged from −45.0× (December 2016) to 2,591× (August 2016); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 4.8× (57.65%)
FY2024 11.2× (2.73%)
FY2023 11.6× (11.87%)
FY2022 13.1× (70.44%)
FY2021 44.4× (3.45%)
FY2020 45.9× 224.71%
FY2019 14.1× (85.09%)
FY2018 94.9× 1,022.60%
FY2017 8.5× (99.63%)
FY2016 2,308× 279.92%

Quarterly newest first

Period EV/Sales Change
Jun 2026 16.4× 26.73%
Mar 2026 12.9× 67.92%
Dec 2025 7.7× 61.43%
Sep 2025 4.8× 78.60%
39 more quarters

Against its own ten years

Low −45.0× High 2,591×
Ten-year median 18.9×
Current reading's percentile 24

EV/Sales against peers

Company EV/Sales
CAI Caris Life Sciences,�Inc. compare 6.8×
CORT Corcept Therapeutics Incorporated compare 7.6×
MDGL Madrigal Pharmaceuticals, Inc. compare 7.8×
ARWR Arrowhead Pharmaceuticals, Inc. 11.2×
KRYS Krystal Biotech, Inc. compare 17.0×
TWST Twist Bioscience Corporation compare 17.3×
PTGX Protagonist Therapeutics, Inc. compare 28.9×
CYTK Cytokinetics, Incorporated compare 65.9×
SYRE Spyre Therapeutics, Inc. compare 7,143×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ARWR